Function of Nogo-A/Nogo-A Receptor in Alzheimer's Disease.
Function of Nogo-A/Nogo-A Receptor in Alzheimer's Disease. CNS Neurosci Ther. 2015 Mar 2; Authors: Xu YQ, Sun ZQ, Wang YT, Xiao F, Chen MW Abstract Nogo-A is a protein inhibiting axonal regeneration, which is considered a major obstacle to nerve regeneration after injury in mammals. Rapid progress has been achieved in new physiopathological function of Nogo-A in Alzheimer's disease in the past decade. Recent research shows that through binding to Nogo-A receptor, Nogo-A plays an important role in Alzheimer's disease (AD) pathogenesis. Particularly, Nogo-A/Nogo-A receptors modulate the generation of amyloid β-protein (Aβ), which is thought to be a major cause of AD. This review describes the recent development of Nogo-A, Nogo-A receptor, and downstream signaling involved in AD and pharmacological basis of therapeutic drugs. We concluded the Nogo-A/Nogo-A receptor provide new insight into potential mechanisms and promising therapy strategies in AD. PMID: 25732725 [PubMed - as supplied by publisher]
Caring for someone with Alzheimer's disease can be both challenging and rewarding. Learn about tips to make it easier, as well as when to seek professional help.
However, no link seen between migraines and vascular dementia
Researchers at private Arizona-based firm NeuroEM Therapeutics tested their transcranial electromagnetic treatment (TEMT) on a group of eight patients with mild or moderate Alzheimer's.
Analyst, 2019, Accepted Manuscript DOI: 10.1039/C9AN00751B, PaperArthur Viode, Stephane Epelbaum, Imen Benyounes, Marc Verny, Bruno Dubois, Christophe Junot, francois Fenaille, Foudil Lamari, Francois Becher Tau and α-synuclein are central in several neurodegenerative diseases, including Alzheimer Disease (AD), Dementia with Lewy bodies (DLB) and Parkinson disease (PD). New analytical methods for precise quantification of cerebrospinal... The content of this RSS Feed (c) The Royal Society of Chemistry
Conditions: Blood Brain Barrier; Alzheimer Disease; Cognitive Dysfunction; Dementia Intervention: Diagnostic Test: Contrast agent enhanced MRI using Gadovist Sponsors: Charite University, Berlin, Germany; Prof. Dr. med. Jochen Fiebach (Senior Physician) Recruiting
Condition: Alzheimer Disease Interventions: Dietary Supplement: Wismemo; Dietary Supplement: Placebo Sponsors: GenMont Biotech Incorporation; Chang Gung Memorial Hospital Not yet recruiting
WEDNESDAY, Sept. 18, 2019 -- Migraines are a significant risk factor for Alzheimer disease (AD) and all-cause dementia, according to a study published online Sept. 4 in the International Journal of Geriatric Psychiatry. Rebecca E. Morton, from...
This Viewpoint describes setbacks in trials of disease-modifying therapies for Alzheimer disease and describes options for future research and clinical care.
ConclusionsWe examined the usefulness of voxel-based statistical analysis for amyloid PET. This method provides objectiveZ-score maps andZ-sum values, which were observed to be helpful as an adjunct to visual interpretation especially for cases with mild or limited A β accumulation. This approach could improve the Aβ detection sensitivity, reduce inter-reader variability, and allow for detailed monitoring of Aβ deposition.Trial registrationThe number of the J-ADNI study isUMIN000001374